Tim Kottke
Mayo Clinic · 56 works · 1,761 citations · h-index 22
Top works
- Histamine H3 Receptor Antagonists Go to Clinics
- Immune-Mediated Antitumor Activity of Reovirus Is Required for Therapy and Is Independent of Direct Viral Oncolysis and Replication
- Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells.
- Oncolytic virus–mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice
- Pharmacologically regulated production of targeted retrovirus from T cells for systemic antitumor gene therapy.
- 2,4-Diaminopyrimidines as histamine H4 receptor ligands—Scaffold optimization and pharmacological characterization
- The inhibition of TNF-α anti-tumoral properties by blocking antibodies promotes tumor growth in a rat model
- A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccines
- Oncolytic virus-derived type I interferon restricts CAR T cell therapy
- Receptor-specific functional efficacies of alkyl imidazoles as dual histamine H3/H4 receptor ligands
- Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics
- Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy
- The histamine H4 receptor: Targeting inflammatory disorders
- Homology Model Adjustment and Ligand Screening with a Pseudoreceptor of the Human Histamine H4 Receptor
- Aryl-1,3,5-triazine derivatives as histamine H4 receptor ligands
- Delivery of CCL21 to Metastatic Disease Improves the Efficacy of Adoptive T-Cell Therapy
- Kojic Acid Derivatives as Histamine H3 Receptor Ligands
- Abstract A49: Systemic oncolytic reovirus for the treatment of primary and secondary brain tumors
- First Metal-Containing Histamine H 3 Receptor Ligands
- Inhibitory Receptors Induced by VSV Viroimmunotherapy Are Not Necessarily Targets for Improving Treatment Efficacy